Next Article in Journal
Molecular Basis of Alcohol-Related Gastric and Colon Cancer
Next Article in Special Issue
Diverse Regulation of Vitamin D Receptor Gene Expression by 1,25-Dihydroxyvitamin D and ATRA in Murine and Human Blood Cells at Early Stages of Their Differentiation
Previous Article in Journal
Mass Spectrometry Based Profiling and Imaging of Various Ginsenosides from Panax ginseng Roots at Different Ages
Previous Article in Special Issue
Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment
Review

The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis

1
Developmental and Molecular Immunology, Department of Biomedicine, University of Basel, Mattenstrasse 28, Basel 4058, Switzerland
2
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Edbgaston, Birmingham B15 2TT, UK
3
Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edbgaston, Birmingham B15 2TT, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Ewa Marcinkowska
Int. J. Mol. Sci. 2017, 18(6), 1115; https://doi.org/10.3390/ijms18061115
Received: 27 April 2017 / Revised: 18 May 2017 / Accepted: 19 May 2017 / Published: 24 May 2017
(This article belongs to the Special Issue The Biology and Treatment of Myeloid Leukaemias)
The cytokine Fms-like tyrosine kinase 3 ligand (FL) is an important regulator of hematopoiesis. Its receptor, Flt3, is expressed on myeloid, lymphoid and dendritic cell progenitors and is considered an important growth and differentiation factor for several hematopoietic lineages. Activating mutations of Flt3 are frequently found in acute myeloid leukemia (AML) patients and associated with a poor clinical prognosis. In the present review we provide an overview of our current knowledge on the role of FL in the generation of blood cell lineages. We examine recent studies on Flt3 expression by hematopoietic stem cells and its potential instructive action at early stages of hematopoiesis. In addition, we review current findings on the role of mutated FLT3 in leukemia and the development of FLT3 inhibitors for therapeutic use to treat AML. The importance of mouse models in elucidating the role of Flt3-ligand in normal and malignant hematopoiesis is discussed. View Full-Text
Keywords: Flt3; hematopoiesis; acute myeloid leukemia (AML); cytokines; Flt3 with internal tandem duplications (FLT3-ITD) Flt3; hematopoiesis; acute myeloid leukemia (AML); cytokines; Flt3 with internal tandem duplications (FLT3-ITD)
Show Figures

Figure 1

MDPI and ACS Style

Tsapogas, P.; Mooney, C.J.; Brown, G.; Rolink, A. The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis. Int. J. Mol. Sci. 2017, 18, 1115. https://doi.org/10.3390/ijms18061115

AMA Style

Tsapogas P, Mooney CJ, Brown G, Rolink A. The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis. International Journal of Molecular Sciences. 2017; 18(6):1115. https://doi.org/10.3390/ijms18061115

Chicago/Turabian Style

Tsapogas, Panagiotis, Ciaran J. Mooney, Geoffrey Brown, and Antonius Rolink. 2017. "The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis" International Journal of Molecular Sciences 18, no. 6: 1115. https://doi.org/10.3390/ijms18061115

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop